A Phospholipase C-γ1–Independent, RasGRP1-ERK–Dependent Pathway Drives Lymphoproliferative Disease in Linker for Activation of T Cells–Y136F Mutant MiceRobert L. Kortum, Connie L. Sommers|The Journal of Immunology|2012Cited by 17
In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapiesNancy E. Sealover, Robert L. Kortum|iScience|2023Cited by 14
Wild-type RAS signaling is an essential therapeutic target in <i>RAS</i> -mutated cancersNancy E. Sealover, Robert L. Kortum|Science Signaling|2025Cited by 3
In situ modeling of acquired resistance to RTK/RAS pathway targeted therapiesNancy E. Sealover, Robert L. Kortum|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 2
SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response in <i>EGFR</i> -mutant lung cancerBrianna R. Daley, Robert L. Kortum|Science Signaling|2025Cited by 2